glp 1 agonist uses GLP-1 Receptor Shortage: Challenges and Solutions in Type 2 Diabetes Care Benefits and drawbacks of GLP-1

The LEADER study showed that liraglutide reduced the risk of Major Adverse Cardiovascular Events (MACE) by 13% in individuals with T2DM and high cardiovascular risk compared to placebo [63]

The risk of seizure is higher in people who take higher doses of CONTRAVE, have certain medical conditions, or take CONTRAVE with certain other medicines

24.5 0.19 g, blood glucose

GLP-1s are an approved treatment for those with a BMI over 30, or a BMI over 27 with at least one comorbidity like type 2 diabetes, hypertension or sleep apnea

In January 2025, Novo Nordisk disclosed key findings from the STEP UP study , a Phase IIIb trial within the global STEP program

N Engl J Med 6 392(10):958971 [DOI] [PubMed] 25.Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M